Protocol AC Guides DME Treatment Approaches

Chirag D. Jhaveri, MD

Show Description +

Chirag D. Jhaveri, MD, presents results from DRCR Retina Network's Protocol AC, which compared aflibercept (Eylea, Regeneron) monotherapy with bevacizumab (Avastin, Genentech/Roche) first.

Posted: 10/10/2022

Keywords:

DRCR Retina Network

•

Protocol AC

•

aflibercept

•

Regeneron Pharmaceuticals

•

Eylea

•

monotherapy

•

Bevacizumab

•

Avastin

•

Genentech

•

Roche

•

retina-meeting-recap

•

Retina Subspecialty Day

Up Next

Name: Protocol AC Guides DME Treatment Approaches
Uploaded: 2022-10-10T20:36:12+00:00
Description: Chirag D. Jhaveri, MD, presents results from DRCR Retina Network's Protocol AC, which compared aflibercept (Eylea, Regeneron) monotherapy with bevacizumab (Avastin, Genentech/Roche) first.

How to Deploy Home OCT

Nancy M. Holekamp, MD

Phase 2 STORM Trial Shows Positive Outcomes

Francis Price, MD

Documenting for Patient Care

Bradley Henriksen, MD

Mask-Associated Dry Eye Syndrome

New Devices in Glaucoma

Oluwatosin Smith, MD, and Qi Cui, MD

Optics 101: Matching Optics to Available Technology

Julie Schallhorn, MD

One-Year Visual Outcomes Following Monocular Implantation With a Small-Aperture IOL

Mark Blecher, MD

The FDA Perspective: The Link Between Medical Devices and Patients

Michelle E. Tarver, MD

The Six Traits of an Inclusive Practice Leader

Rupa Wong, MD

$A Refractive Surgery Journey and Lessons Learned$

A Refractive Surgery Journey and Lessons Learned

Sheraz M. Daya, MD, FACP, FACS, FRCS(Ed), FRCOphth

A Look at a New Shape-Changing IOL

Eric D. Donnenfeld, MD

IOL Calculations: The Internet Way

Oliver Findl, MD, MBA

Corneal Ulceration in Patients With Ocular Graft-Versus-Host Disease

Rahul Tonk, MD; Paula Sepulveda, MD

Evaluating the Efficacy of a ROCK Inhibitor for the Treatment of Corneal Edema

Himani Goyal, MD; Adanna Udeh, MD

Dr. Avery’s AAO 2022 Can’t-Miss Retina Sessions

Robert L. Avery, MD

Ocular Inflammation in Retinal Gene Therapies

Glenn C. Yiu, MD, PhD

The State of Macular Hole Surgery

Sophie J. Bakri, MD

A Look at Private Equity in Retina

John T. Thompson, MD

Avoid PDR Complications With Early Vitrectomy

Maria H. Berrocal, MD

GA Update: Phase 3 Data for Pegcetacoplan

Charles C. Wykoff, MD, PhD

Phase 2/3 Data for High-Dose Aflibercept for DME

David M. Brown, MD

Back to All Videos

Protocol AC Guides DME Treatment Approaches

Chirag D. Jhaveri, MD

Chirag D. Jhaveri, MD, presents results from DRCR Retina Network's Protocol AC, which compared aflibercept (Eylea, Regeneron) monotherapy with bevacizumab (Avastin, Genentech/Roche) first.

Posted: 10/10/2022

Keywords:

DRCR Retina Network

•

Protocol AC

•

aflibercept

•

Regeneron Pharmaceuticals

•

Eylea

•

monotherapy

•

Bevacizumab

•

Avastin

•

Genentech

•

Roche

•

retina-meeting-recap

•

Retina Subspecialty Day

Please log in to leave a comment.

Meeting Coverage:

American Academy of Ophthalmology

Protocol AC Guides DME Treatment Approaches

Up Next

Protocol AC Guides DME Treatment Approaches

More From AAO: 2022 Coverage